Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling

G. J. Yuen, G. L. Drusano, C. Fletcher, E. Capparelli, J. D. Connor, J. P. Lalezari, L. Drew, S. Follansbee, D. Busch, M. Jacobson, S. A. Spector, K. Squires, W. Buhles

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)infected patients through the use of nonlinear mixed- effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41% faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.

Original languageEnglish (US)
Pages (from-to)2350-2352
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number10
DOIs
StatePublished - Jan 1 1995

Fingerprint

Ganciclovir
Population
Cytomegalovirus
HIV
Creatinine
Cytomegalovirus Retinitis
Serum
Pharmacokinetics
Urine
Transplants
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. / Yuen, G. J.; Drusano, G. L.; Fletcher, C.; Capparelli, E.; Connor, J. D.; Lalezari, J. P.; Drew, L.; Follansbee, S.; Busch, D.; Jacobson, M.; Spector, S. A.; Squires, K.; Buhles, W.

In: Antimicrobial Agents and Chemotherapy, Vol. 39, No. 10, 01.01.1995, p. 2350-2352.

Research output: Contribution to journalArticle

Yuen, GJ, Drusano, GL, Fletcher, C, Capparelli, E, Connor, JD, Lalezari, JP, Drew, L, Follansbee, S, Busch, D, Jacobson, M, Spector, SA, Squires, K & Buhles, W 1995, 'Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling', Antimicrobial Agents and Chemotherapy, vol. 39, no. 10, pp. 2350-2352. https://doi.org/10.1128/AAC.39.10.2350
Yuen, G. J. ; Drusano, G. L. ; Fletcher, C. ; Capparelli, E. ; Connor, J. D. ; Lalezari, J. P. ; Drew, L. ; Follansbee, S. ; Busch, D. ; Jacobson, M. ; Spector, S. A. ; Squires, K. ; Buhles, W. / Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. In: Antimicrobial Agents and Chemotherapy. 1995 ; Vol. 39, No. 10. pp. 2350-2352.
@article{d6bec83dd0cb420f9323a536a501777b,
title = "Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling",
abstract = "We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)infected patients through the use of nonlinear mixed- effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41{\%} faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.",
author = "Yuen, {G. J.} and Drusano, {G. L.} and C. Fletcher and E. Capparelli and Connor, {J. D.} and Lalezari, {J. P.} and L. Drew and S. Follansbee and D. Busch and M. Jacobson and Spector, {S. A.} and K. Squires and W. Buhles",
year = "1995",
month = "1",
day = "1",
doi = "10.1128/AAC.39.10.2350",
language = "English (US)",
volume = "39",
pages = "2350--2352",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling

AU - Yuen, G. J.

AU - Drusano, G. L.

AU - Fletcher, C.

AU - Capparelli, E.

AU - Connor, J. D.

AU - Lalezari, J. P.

AU - Drew, L.

AU - Follansbee, S.

AU - Busch, D.

AU - Jacobson, M.

AU - Spector, S. A.

AU - Squires, K.

AU - Buhles, W.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)infected patients through the use of nonlinear mixed- effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41% faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.

AB - We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)infected patients through the use of nonlinear mixed- effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41% faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=0029148378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029148378&partnerID=8YFLogxK

U2 - 10.1128/AAC.39.10.2350

DO - 10.1128/AAC.39.10.2350

M3 - Article

C2 - 8619596

AN - SCOPUS:0029148378

VL - 39

SP - 2350

EP - 2352

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -